FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1969507718> ?p ?o ?g. }

• W1969507718 endingPage "854" @default.
• W1969507718 startingPage "848" @default.
• W1969507718 abstract "No AccessJournal of UrologyAdult Urology1 Mar 2011Efficacy of a Second Line Luteinizing Hormone-Releasing Hormone Agonist After Advanced Prostate Cancer Biochemical Recurrence Nathan Lawrentschuk, Kimberly Fernandes, David Bell, Jack Barkin, and Neil Fleshner Nathan LawrentschukNathan Lawrentschuk More articles by this author , Kimberly FernandesKimberly Fernandes More articles by this author , David BellDavid Bell More articles by this author , Jack BarkinJack Barkin Financial interest and/or other relationship with Astellas, GlaxoSmithKline, AstraZeneca, Pfizer and Merck. More articles by this author , and Neil FleshnerNeil Fleshner Financial interest and/or other relationship with Sanofi-Aventis, Bio-Advantex, Novartis, AstraZeneca, GlaxoSmithKline, Merck and Pfizer. More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2010.10.055AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: Men with castrate resistant prostate cancer have limited treatment options. Although luteinizing hormone-releasing hormone agonists are in the same class, they are slightly different in their pharmacology. We determined whether rechallenging patients with prostate cancer, who were receiving a luteinizing hormone-releasing hormone analogue but had progression, with a different luteinizing hormone-releasing hormone analogue (goserelin or leuprolide acetate) would result in a prostate specific antigen response. Secondary objectives were to calculate the PSA response and determine whether sequence order impacted the response. Materials and Methods: We performed a retrospective, ethics approved review of the records of patients with prostate cancer at multiple institutions who received a luteinizing hormone-releasing hormone analogue (goserelin or leuprolide acetate), experienced progression, as measured by 2 consecutive prostate specific antigen increases, and were rechallenged with the other analogue (goserelin or leuprolide acetate). Prostate specific antigen and relevant clinical data were obtained and statistical analysis was done. Results: Of 39 available men 27 (69%) had decreased prostate specific antigen after 3 months of switching regimens. The median change in prostate specific antigen was −1.5 (IQR −10.0, 0.8), indicating a statistically significant decrease (p = 0.01). The median percent prostate specific antigen change for leuprolide acetate to goserelin was −69.3% (IQR −81.5, 26.2) and for goserelin to leuprolide acetate it was −6.4% (IQR −61.7, 21.8, p = 0.05). Median time to a subsequent prostate specific antigen increase was 5.2 months (95% CI 3.5–17.4). Conclusions: Prostate specific antigen decreased after switching luteinizing hormone-releasing hormone therapies. This decrease appeared most significant in the group that switched from leuprolide acetate to goserelin. The duration of response after switching was approximately 5 months. The study is limited by its retrospective nature but should encourage prospective evaluation of this observation. References 1 : Cancer statistics, 2009. CA Cancer J Clin2009; 59: 225. Google Scholar 2 : Advanced prostate cancer: immediate or deferred hormone therapy?. Eur Urol2001; 39: 15. Google Scholar 3 : Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med2009; 360: 2516. Google Scholar 4 : Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med1999; 341: 1781. Crossref, Medline, Google Scholar 5 : The management of prostate cancer in patients with a rising prostate-specific antigen level. BJU Int2000; 86: 181. Google Scholar 6 : New developments in the pharmacological management of prostate cancer. BJU Int2000; 85: 31. Google Scholar 7 : Update on castrate-resistant prostate cancer: 2010. Curr Opin Oncol2010; 22: 263. Google Scholar 8 : Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol2009; 27: 3742. Google Scholar 9 : Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol2008; 26: 242. Google Scholar 10 : Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol2006; 24: 3089. Google Scholar 11 : Comparative efficacy of triptorelin pamoate and leuprolide acetate in men with advanced prostate cancer. BJU Int2003; 92: 226. Google Scholar 12 : Duration of first off-treatment interval is prognostic for time to castration resistance and death in men with biochemical relapse of prostate cancer treated on a prospective trial of intermittent androgen deprivation. J Clin Oncol2010; 28: 2668. Google Scholar 13 : The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res1941; 1: 293. Google Scholar 14 : Isolation and properties of the FSH and LH-releasing hormone. Biochem Biophys Res Commun1971; 43: 393. Google Scholar 15 : Decreasing use of luteinizing hormone-releasing hormone agonists in the United States is Independent of Reimbursement Changes: A Medicare and Veterans Health Administration claims analysis. J Urol2009; 182: 255. Link, Google Scholar 16 : Metabolic complications of androgen deprivation therapy for prostate cancer. J Urol2009; 181: 1998. Link, Google Scholar 17 : A double-blind randomized crossover study of oral thalidomide versus placebo for androgen dependent prostate cancer treated with intermittent androgen ablation. J Urol2009; 181: 1104. Link, Google Scholar 18 : How good do current LHRH agonists control testosterone?: Can this be improved with Eligard? . Eur Urol2005; : 30. Google Scholar 19 : Does prolonged combined androgen blockade have survival benefits over short-term combined androgen blockade therapy?. Urology2000; 55: 391. Google Scholar 20 : Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: final report of a double-blind, randomized, multicenter trial: Casodex Combination Study Group . Urology1997; 50: 330. Google Scholar 21 : Comparison of goserelin and leuprolide in combined androgen blockade therapy. Urology1998; 52: 82. Google Scholar 22 : Comparison of single-agent androgen suppression for advanced prostate cancer. Rev Urol2005; 7: S3. Google Scholar 23 : Comparative review of anastrozole, letrozole and exemestane in the management of early breast cancer. Expert Opin Pharmacother2009; 10: 1435. Google Scholar 24 : The breast cancer continuum in hormone-receptor-positive breast cancer in postmenopausal women: evolving management options focusing on aromatase inhibitors. Ann Oncol2008; 19: 16. Google Scholar 25 : Efficacy over time of LHRH analogs in the treatment of PCa—a prospective analysis using serum testosterone to determine dosing intervals. Urology2009; 73: 631. Google Scholar 26 : Effects of the duration of therapy with the LHRH agonist D-ser (BUT)6 Azgly10-LHRH (ICI 118–630) on the steroid hormone content and the morphology of human testicular tissue in the treatment of patients with advanced prostate cancer. Urol Res1991; 19: 19. Google Scholar 27 : Luteinizing hormone-releasing hormone (LHRH) agonists for treatment of advanced prostatic carcinoma. Urology1989; 33: 42. Google Scholar 28 : Serum testosterone-based luteinizing hormone-releasing hormone agonist redosing schedule for chronic androgen ablation: a phase I assessment. Urology1999; 54: 694. Crossref, Medline, Google Scholar 29 : Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy. J Urol2007; 178: 1290. Link, Google Scholar © 2011 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetailsCited byAtala A (2018) Re: Effects of Luteinizing Hormone Receptor Signaling in Prostate Cancer CellsJournal of Urology, VOL. 194, NO. 5, (1504-1505), Online publication date: 1-Nov-2015. Volume 185Issue 3March 2011Page: 848-854 Advertisement Copyright & Permissions© 2011 by American Urological Association Education and Research, Inc.Keywordsprostatic neoplasmsprostateprostate-specific antigenleuprolidegoserelinAcknowledgmentsStudy monitoring and data collection were done by CMX Research, Oakville, Canada. AstraZeneca Canada, Mississauga, Ontario, Canada, provided administrative support.Metrics Author Information Nathan Lawrentschuk More articles by this author Kimberly Fernandes More articles by this author David Bell More articles by this author Jack Barkin Financial interest and/or other relationship with Astellas, GlaxoSmithKline, AstraZeneca, Pfizer and Merck. More articles by this author Neil Fleshner Financial interest and/or other relationship with Sanofi-Aventis, Bio-Advantex, Novartis, AstraZeneca, GlaxoSmithKline, Merck and Pfizer. More articles by this author Expand All Advertisement PDF downloadLoading ..." @default.
• W1969507718 created "2016-06-24" @default.
• W1969507718 creator A5007710281 @default.
• W1969507718 creator A5007732924 @default.
• W1969507718 creator A5029784853 @default.
• W1969507718 creator A5073537684 @default.
• W1969507718 creator A5081221251 @default.
• W1969507718 date "2011-03-01" @default.
• W1969507718 modified "2023-09-23" @default.
• W1969507718 title "Efficacy of a Second Line Luteinizing Hormone-Releasing Hormone Agonist After Advanced Prostate Cancer Biochemical Recurrence" @default.
• W1969507718 cites W1968392281 @default.
• W1969507718 cites W1978078070 @default.
• W1969507718 cites W1985587689 @default.
• W1969507718 cites W1987169832 @default.
• W1969507718 cites W2005118637 @default.
• W1969507718 cites W2006838623 @default.
• W1969507718 cites W2044709713 @default.
• W1969507718 cites W2062090998 @default.
• W1969507718 cites W2073089122 @default.
• W1969507718 cites W2079691060 @default.
• W1969507718 cites W2081522216 @default.
• W1969507718 cites W2092563355 @default.
• W1969507718 cites W2101567085 @default.
• W1969507718 cites W2101606728 @default.
• W1969507718 cites W2101995865 @default.
• W1969507718 cites W2109809089 @default.
• W1969507718 cites W2117301449 @default.
• W1969507718 cites W2128543455 @default.
• W1969507718 cites W2134789018 @default.
• W1969507718 cites W2149752186 @default.
• W1969507718 cites W2159437944 @default.
• W1969507718 cites W2162460707 @default.
• W1969507718 cites W2165542862 @default.
• W1969507718 cites W2168286690 @default.
• W1969507718 cites W2170066377 @default.
• W1969507718 cites W2337912524 @default.
• W1969507718 cites W3177389569 @default.
• W1969507718 doi "https://doi.org/10.1016/j.juro.2010.10.055" @default.
• W1969507718 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21239017" @default.
• W1969507718 hasPublicationYear "2011" @default.
• W1969507718 type Work @default.
• W1969507718 sameAs 1969507718 @default.
• W1969507718 citedByCount "28" @default.
• W1969507718 countsByYear W19695077182012 @default.
• W1969507718 countsByYear W19695077182013 @default.
• W1969507718 countsByYear W19695077182014 @default.
• W1969507718 countsByYear W19695077182015 @default.
• W1969507718 countsByYear W19695077182016 @default.
• W1969507718 countsByYear W19695077182017 @default.
• W1969507718 countsByYear W19695077182018 @default.
• W1969507718 countsByYear W19695077182020 @default.
• W1969507718 countsByYear W19695077182021 @default.
• W1969507718 countsByYear W19695077182022 @default.
• W1969507718 crossrefType "journal-article" @default.
• W1969507718 hasAuthorship W1969507718A5007710281 @default.
• W1969507718 hasAuthorship W1969507718A5007732924 @default.
• W1969507718 hasAuthorship W1969507718A5029784853 @default.
• W1969507718 hasAuthorship W1969507718A5073537684 @default.
• W1969507718 hasAuthorship W1969507718A5081221251 @default.
• W1969507718 hasConcept C121608353 @default.
• W1969507718 hasConcept C126322002 @default.
• W1969507718 hasConcept C126894567 @default.
• W1969507718 hasConcept C134018914 @default.
• W1969507718 hasConcept C143998085 @default.
• W1969507718 hasConcept C170493617 @default.
• W1969507718 hasConcept C2778575703 @default.
• W1969507718 hasConcept C2778938600 @default.
• W1969507718 hasConcept C2780192828 @default.
• W1969507718 hasConcept C71315377 @default.
• W1969507718 hasConcept C71924100 @default.
• W1969507718 hasConceptScore W1969507718C121608353 @default.
• W1969507718 hasConceptScore W1969507718C126322002 @default.
• W1969507718 hasConceptScore W1969507718C126894567 @default.
• W1969507718 hasConceptScore W1969507718C134018914 @default.
• W1969507718 hasConceptScore W1969507718C143998085 @default.
• W1969507718 hasConceptScore W1969507718C170493617 @default.
• W1969507718 hasConceptScore W1969507718C2778575703 @default.
• W1969507718 hasConceptScore W1969507718C2778938600 @default.
• W1969507718 hasConceptScore W1969507718C2780192828 @default.
• W1969507718 hasConceptScore W1969507718C71315377 @default.
• W1969507718 hasConceptScore W1969507718C71924100 @default.
• W1969507718 hasIssue "3" @default.
• W1969507718 hasLocation W19695077181 @default.
• W1969507718 hasLocation W19695077182 @default.
• W1969507718 hasOpenAccess W1969507718 @default.
• W1969507718 hasPrimaryLocation W19695077181 @default.
• W1969507718 hasRelatedWork W1988486434 @default.
• W1969507718 hasRelatedWork W1991634850 @default.
• W1969507718 hasRelatedWork W1994104316 @default.
• W1969507718 hasRelatedWork W1999007392 @default.
• W1969507718 hasRelatedWork W2012502375 @default.
• W1969507718 hasRelatedWork W2027913950 @default.
• W1969507718 hasRelatedWork W2047880909 @default.
• W1969507718 hasRelatedWork W2053271595 @default.
• W1969507718 hasRelatedWork W2073502422 @default.
• W1969507718 hasRelatedWork W2121299924 @default.
• W1969507718 hasVolume "185" @default.
• W1969507718 isParatext "false" @default.

• next